{"id":966235,"date":"2026-05-21T18:26:02","date_gmt":"2026-05-21T22:26:02","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/syndax-announces-four-revuforj-revumenib-abstracts-accepted-for-asco-2026-including-an-oral-presentation-of-post-transplant-data\/"},"modified":"2026-05-21T18:26:02","modified_gmt":"2026-05-21T22:26:02","slug":"syndax-announces-four-revuforj-revumenib-abstracts-accepted-for-asco-2026-including-an-oral-presentation-of-post-transplant-data","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/syndax-announces-four-revuforj-revumenib-abstracts-accepted-for-asco-2026-including-an-oral-presentation-of-post-transplant-data\/","title":{"rendered":"Syndax Announces Four Revuforj\u00ae (revumenib) Abstracts Accepted for ASCO 2026, Including an Oral Presentation of Post-Transplant Data"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"center\">\n        <em>\u2013 Oral presentation will highlight favorable outcomes observed among 21 adults and children with KMT2Ar, NPM1m, or NUP98r acute leukemia who received revumenib post-transplant \u2013<\/em>\n      <\/p>\n<p align=\"center\">\n        <em>\u2013 Data underscoring unique aspects of revumenib\u2019s PK profile, including the ability to administer it with gastric acid reducing agents and low-fat meals, will be presented \u2013 <\/em>\n      <\/p>\n<p align=\"center\">\n        <em>\u2013 Design of ongoing pivotal trials of revumenib plus low or high-intensity chemotherapy in newly diagnosed NPM1m or KMT2Ar acute leukemia will be highlighted \u2013<\/em><br \/>\n        \n      <\/p>\n<p align=\"justify\">NEW YORK, May  21, 2026  (GLOBE NEWSWIRE) &#8212; Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced the acceptance of four Revuforj<sup>\u00ae<\/sup> (revumenib) abstracts for presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 29 \u2013 June 2, 2026, in Chicago.<\/p>\n<p align=\"justify\">\u201cOur strong presence at ASCO highlights our scientific leadership in menin inhibition and our deep commitment to advancing cancer care. We and our collaborators will present new evidence that moves the field forward, including an oral presentation of data showing favorable outcomes among patients who received revumenib in the post-transplant setting. This presentation will provide additional evidence in an area of high physician interest and inform further clinical research,\u201d said Nick Botwood, MBBS, Head of Research &amp; Development and Chief Medical Officer at Syndax.<\/p>\n<p align=\"justify\">Dr. Botwood continued, \u201cBuilding on the strong body of efficacy data that distinguishes revumenib, we also look forward to presenting PK data which highlight other important aspects of its profile, including the ability to administer revumenib with commonly prescribed gastric acid reducing agents without the risk of reducing efficacy.\u201d<\/p>\n<p align=\"justify\">\n        <strong>Key revumenib presentations at ASCO 2026:<\/strong>\n      <\/p>\n<ul>\n<li style=\"text-align:justify\">An oral presentation of safety and efficacy data from 21 adults and children with KMT2Ar, NPM1m, or NUP98r acute leukemia who received revumenib as maintenance following hematopoietic stem cell transplantation (HSCT). The presentation will include the observed overall survival and relapse rate, along with a comparison to a historical cohort of patients with the same genetic subtypes of acute leukemia treated prior to the advent of revumenib.<\/li>\n<li style=\"text-align:justify\">A poster presentation characterizing the pharmacokinetics (PK) of revumenib, with an emphasis on differentiating aspects of its PK profile, including the ability to 1) administer revumenib with gastric acid reducing agents without the risk of reduced efficacy, 2) ensure optimal exposure in the presence of strong CYP3A4 inhibitors using a clear revumenib dose adjustment strategy, and 3) administer revumenib with low-fat meals.<\/li>\n<\/ul>\n<p align=\"justify\">The accepted abstracts listed below are now available online on the ASCO conference website. Copies of the oral and poster presentations will be made available in the \u2018Publications &amp; Meeting Presentations\u2019 section of the Syndax website after the data are presented.<\/p>\n<p align=\"justify\">\n        <strong>Full list of revumenib abstracts accepted for presentation at ASCO 2026 (all times in CDT): <\/strong>\n      <\/p>\n<table style=\"border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;border-collapse: collapse;width:100%;border-collapse:collapse\">\n<tr>\n<td style=\"max-width:53%;width:53%;min-width:53%;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">\n            <strong>Abstract Titles<\/strong>\n          <\/td>\n<td style=\"max-width:47%;width:47%;min-width:47%;border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">\n            <strong>Presentation Details<\/strong>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">Revumenib as maintenance for AML following allogeneic stem cell transplantation<\/td>\n<td style=\"border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">Abstract number: 6505<br \/>Oral presentation<br \/>Tuesday, June 2, 9:45 am-12:45 pm<\/td>\n<\/tr>\n<tr>\n<td style=\"border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">Pharmacokinetic (PK) assessment of revumenib in patients with relapsed\/refractory (R\/R) acute leukemias harboring a <em>KMT2A<\/em> rearrangement (<em>KMT2A<\/em>r) or <em>NPM1<\/em> mutation (<em>NPM1<\/em>m): Impact of food and concomitant medications<\/td>\n<td style=\"border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">Abstract number: 6528<br \/>Poster presentation<br \/>Monday, June 1, 9:00 am \u2013 12:00 pm<\/td>\n<\/tr>\n<tr>\n<td style=\"border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">A phase 3 study of revumenib plus venetoclax\/azacitidine in adults with newly diagnosed <em>NPM1<\/em>-mutated or <em>KMT2A<\/em>-rearranged acute myeloid leukemia ineligible for intensive chemotherapy (EVOLVE-2\/HO177\/AMLSG35-24\/ACT-HOV-AML-002): Trial in progress<\/td>\n<td style=\"border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">Abstract number: TPS6600<br \/>Poster presentation<br \/>Monday, June 1, 9:00 am \u2013 12:00 pm<\/td>\n<\/tr>\n<tr>\n<td style=\"border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">A phase 3 study of revumenib in combination with intensive chemotherapy in patients with newly diagnosed <em>NPM1<\/em>-mutated acute myeloid leukemia (REVEAL-ND NPM1): Trial in progress<\/td>\n<td style=\"border-top: solid black 1pt;border-right: solid black 1pt;border-bottom: solid black 1pt;border-left: solid black 1pt;vertical-align: top\">Abstract number: TPS6602<br \/>Poster presentation<br \/>Monday, June 1, 9:00 am \u2013 12:00 pm<\/td>\n<\/tr>\n<\/table>\n<p>\n        <strong><br \/>\n          <br \/>About<\/strong><br \/>\n        <strong>Revuforj<\/strong><br \/>\n        <sup><br \/>\n          <strong>\u00ae<\/strong><br \/>\n        <\/sup><br \/>\n        <strong> (revumenib)<\/strong>\n      <\/p>\n<p align=\"justify\">Revuforj (revumenib) is an oral, first-in-class menin inhibitor that is FDA approved for the treatment of relapsed or refractory (R\/R) acute leukemia with a lysine methyltransferase 2A gene (KMT2A) translocation as determined by an FDA-authorized test in adult and pediatric patients one year and older. Revuforj is also indicated for the treatment of R\/R acute myeloid leukemia (AML) with a susceptible nucleophosmin 1 (NPM1) mutation in adult and pediatric patients one year and older who have no satisfactory alternative treatment options.<\/p>\n<p align=\"justify\">Multiple trials of revumenib are ongoing or planned across the treatment landscape, including in combination with standard of care therapies in newly diagnosed patients with NPM1m or KMT2Ar AML.<\/p>\n<p>\n        <strong><br \/>\n          <u>Revuforj (revumenib)<\/u><br \/>\n        <\/strong>\n      <\/p>\n<p>\n        <strong>IMPORTANT SAFETY INFORMATION<\/strong>\n      <\/p>\n<p align=\"justify\">\n        <strong>WARNING: DIFFERENTIATION SYNDROME, QTc PROLONGATION, and TORSADES DE POINTES<\/strong>\n      <\/p>\n<p align=\"justify\">\n        <strong>Differentiation syndrome, which can be fatal, has occurred with Revuforj. Signs and symptoms may include fever, dyspnea, hypoxia, pulmonary infiltrates, pleural or pericardial effusions, rapid weight gain or peripheral edema, hypotension, and renal dysfunction. If differentiation syndrome is suspected, immediately initiate corticosteroid therapy and hemodynamic monitoring until symptom resolution.<\/strong>\n      <\/p>\n<p align=\"justify\">\n        <strong>QTc prolongation and Torsades de Pointes have occurred in patients receiving Revuforj. Correct hypokalemia and hypomagnesemia prior to and during treatment. Do not initiate Revuforj in patients with QTcF &gt; 450 msec. If QTc interval prolongation occurs, interrupt, reduce, or permanently discontinue Revuforj.<\/strong>\n      <\/p>\n<p align=\"justify\">\n        <strong>WARNINGS AND PRECAUTIONS<\/strong>\n      <\/p>\n<p align=\"justify\">\n        <strong>Differentiation Syndrome:<\/strong> Revuforj can cause fatal or life-threatening differentiation syndrome (DS). Symptoms of DS, including those seen in patients treated with Revuforj, include fever, dyspnea, hypoxia, peripheral edema, pleuropericardial effusion, acute renal failure, rash, and\/or hypotension.<\/p>\n<p align=\"justify\">In clinical trials, DS occurred in 60 (25%) of 241 patients treated with Revuforj at the recommended dosage for relapsed or refractory acute leukemia. Among those with a KMT2A translocation, DS occurred in 33% of patients with acute myeloid leukemia (AML), 33% of patients with mixed-phenotype acute leukemia (MPAL), and 9% of patients with acute lymphoblastic leukemia (ALL); DS occurred in 18% of patients with NPM1m AML. DS was Grade 3 or 4 in 12% of patients and fatal in 2 patients. The median time to initial onset was 9 days (range 3-41 days). Some patients experienced more than 1 DS event. Treatment interruption was required for 7% of patients, and treatment was withdrawn for 1%.<\/p>\n<p align=\"justify\">Reduce the white blood cell count to less than 25 Gi\/L prior to starting Revuforj. If DS is suspected, immediately initiate treatment with systemic corticosteroids (e.g., dexamethasone 10 mg IV every 12 hours in adults or dexamethasone 0.25 mg\/kg\/dose IV every 12 hours in pediatric patients weighing less than 40 kg) for a minimum of 3 days and until resolution of signs and symptoms. Institute supportive measures and hemodynamic monitoring until improvement. Interrupt Revuforj if severe signs and\/or symptoms persist for more than 48 hours after initiation of systemic corticosteroids, or earlier if life-threatening symptoms occur such as pulmonary symptoms requiring ventilator support. Restart steroids promptly if DS recurs after tapering corticosteroids<strong>.<\/strong><\/p>\n<p align=\"justify\">\n        <strong>QTc Interval Prolongation and Torsades de Pointes: <\/strong>Revuforj can cause QT (QTc) interval prolongation and Torsades de Pointes.<\/p>\n<p align=\"justify\">Of the 241 patients treated with Revuforj at the recommended dosage for relapsed or refractory acute leukemia in clinical trials, QTc interval prolongation was reported as an adverse reaction in 86 (36%) patients. QTc interval prolongation was Grade 3 in 15% and Grade 4 in 2%. The heart-rate corrected QT interval (using Fridericia\u2019s method) (QTcF) was greater than 500 msec in 10%, and the increase from baseline QTcF was greater than 60 msec in 24%. Revuforj dose reduction was required for 7% due to QTc interval prolongation. QTc prolongation occurred in 21% of the 34 patients less than 17 years old, 35% of the 146 patients 17 years to less than 65 years old, and 46% of the 61 patients 65 years or older. One patient had a fatal outcome of cardiac arrest, and one patient had non-sustained Torsades de Pointes.<\/p>\n<p align=\"justify\">Correct electrolyte abnormalities, including hypokalemia and hypomagnesemia, prior to and throughout treatment with Revuforj. Perform an electrocardiogram (ECG) prior to initiation of Revuforj, and do not initiate Revuforj in patients with QTcF &gt;450 msec. Perform an ECG at least once weekly for the first 4 weeks and at least monthly thereafter. In patients with congenital long QTc syndrome, congestive heart failure, electrolyte abnormalities, or those who are taking medications known to prolong the QTc interval, more frequent ECG monitoring may be necessary. Concomitant use with drugs known to prolong the QTc interval may increase the risk of QTc interval prolongation.<\/p>\n<ul>\n<li style=\"text-align:justify\">Interrupt Revuforj if QTcF increases &gt;480 msec and &lt;500 msec, and restart Revuforj at the same dose twice daily after the QTcF interval returns to \u2264480 msec<\/li>\n<li style=\"text-align:justify\">Interrupt Revuforj if QTcF increases &gt;500 msec or by &gt;60 msec from baseline, and restart Revuforj twice daily at the lower-dose level after the QTcF interval returns to \u2264480 msec<\/li>\n<li style=\"text-align:justify\">Permanently discontinue Revuforj in patients with ventricular arrhythmias and in those who develop QTc interval prolongation with signs or symptoms of life-threatening arrhythmia<\/li>\n<\/ul>\n<p align=\"justify\">\n        <strong>Embryo-Fetal Toxicity: <\/strong>Revuforj can cause fetal harm when administered to a pregnant woman. Advise pregnant women of the potential risk to a fetus. Advise females of reproductive potential and males with female partners of reproductive potential to use effective contraception during treatment with Revuforj and for 4 months after the last dose of Revuforj.<\/p>\n<p align=\"justify\">\n        <strong>ADVERSE REACTIONS<\/strong>\n      <\/p>\n<p align=\"justify\">\n        <strong>Fatal adverse reactions <\/strong>occurred in 9 (4%) patients who received Revuforj, including 4 with sudden death, 2 with differentiation syndrome, 2 with hemorrhage, and 1 with cardiac arrest.<\/p>\n<p align=\"justify\">\n        <strong>Serious adverse reactions<\/strong> were reported in 184 (76%) patients. The most frequent serious adverse reactions (\u226510%) were infection (29%), febrile neutropenia (20%), bacterial infection (15%), differentiation syndrome (13%), and hemorrhage (11%).<\/p>\n<p align=\"justify\">The <strong>most common adverse reactions<\/strong> (\u226520%) including laboratory abnormalities, were phosphate increased (51%), hemorrhage (48%), nausea (48%), infection without identified pathogen (46%), aspartate aminotransferase increased (44%), alanine aminotransferase increased (40%), creatinine increased (38%), musculoskeletal pain (37%), febrile neutropenia (37%), electrocardiogram QT prolonged (36%), potassium decreased (34%), parathyroid hormone intact increased (34%), alkaline phosphatase increased (33%), diarrhea (29%), bacterial infection (27%), triglycerides increased (27%), phosphate decreased (25%), differentiation syndrome (25%), fatigue (24%), edema (24%), viral infection (23%), decreased appetite (20%), and constipation (20%).<\/p>\n<p align=\"justify\">\n        <strong>DRUG INTERACTIONS<\/strong>\n      <\/p>\n<p align=\"justify\">Drug interactions can occur when Revuforj is concomitantly used with:<\/p>\n<ul>\n<li style=\"text-align:justify\">Strong CYP3A4 inhibitors: reduce Revuforj dose<\/li>\n<li style=\"text-align:justify\">Strong or moderate CYP3A4 inducers: avoid concomitant use with Revuforj<\/li>\n<li style=\"text-align:justify\">QTc-prolonging drugs: avoid concomitant use with Revuforj. If concomitant use is unavoidable, obtain ECGs when initiating, during concomitant use, and as clinically indicated. Withhold Revuforj if the QTc interval is &gt;480 msec. Restart Revuforj after the QTc interval returns to \u2264480 msec<\/li>\n<\/ul>\n<p align=\"justify\">\n        <strong>SPECIFIC POPULATIONS<\/strong>\n      <\/p>\n<p align=\"justify\">\n        <strong>Lactation: <\/strong>advise lactating women not to breastfeed during treatment with Revuforj and for 1 week after the last dose.\u00a0\u00a0<\/p>\n<p align=\"justify\">\n        <strong>Pregnancy and testing: <\/strong>Revuforj can cause fetal harm when administered to a pregnant woman. Verify pregnancy status in females of reproductive potential within 7 days prior to initiating Revuforj.<\/p>\n<p align=\"justify\">\n        <strong>Infertility: <\/strong>based on findings in animals, Revuforj may impair fertility. The effects on fertility were reversible.<\/p>\n<p align=\"justify\">\n        <strong>Pediatric: <\/strong>monitor bone growth and development in pediatric patients<strong>.<\/strong><\/p>\n<p align=\"justify\">\n        <strong>Geriatric: <\/strong>no overall differences were observed in the effectiveness of Revuforj between patients who were 65 years and older, and younger patients. Compared to younger patients, the incidences of QTc prolongation and edema were higher in patients 65 years and older.<\/p>\n<p align=\"justify\">\n        <strong>To report SUSPECTED ADVERSE REACTIONS, contact Syndax Pharmaceuticals at 1-888-539-3REV or FDA at 1-800-FDA-1088 or <\/strong><br \/>\n        <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=abEcvqN36G-OpmnmeKAQhtKccYv6MN3ZaepnBZxu2usueBrenq5o7K75WKymwPItHVvVVA-qrNG1NE3CFFKjmtwT4GUr0z1Zf0TnJ1jgoIk=\" rel=\"nofollow\" target=\"_blank\">www.fda.gov\/medwatch<\/a><br \/>\n        <strong>.<\/strong>\n      <\/p>\n<p align=\"justify\">\n        <strong>Please see <\/strong><br \/>\n        <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=-wViwXwwVcmbbiCm7ZPbQ3hU4TP0BnvetXhnn9DMTDW1ZvhjjLiz03isd7Czo3O_A4s8llxr698pPAd0D5Xigc7TSamFQ8lWXO-kE4uZy70b12M_R0dWHGd9ZLXndZ3pSw10mhP0nvzJR-nJLe-nhQ==\" rel=\"nofollow\" target=\"_blank\">Full Prescribing Information<\/a><br \/>\n        <strong>, including BOXED WARNINGS.<\/strong>\n      <\/p>\n<p align=\"justify\">\n        <strong>About Syndax <\/strong>\n      <\/p>\n<p align=\"justify\">Syndax Pharmaceuticals\u00a0is a commercial-stage biopharmaceutical company advancing innovative cancer therapies. Highlights of the Company&#8217;s pipeline include Revuforj<sup>\u00ae<\/sup> (revumenib), an FDA-approved menin inhibitor, and Niktimvo\u2122 (axatilimab-csfr), an FDA-approved monoclonal antibody that blocks the colony stimulating factor 1 (CSF-1) receptor. Fueled by our commitment to reimagining cancer care, Syndax is working to unlock the full potential of its pipeline and is conducting several clinical trials across the continuum of treatment. For more information, please visit\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=4DcLy7OzepLcPVePWq3LNgEqT9kkhq43TanOBvhHMzg6GkLCteRhNQPtas712eyr8AxKX90mRIaMTWt45r2N3Cm68cpp3nSU-BfnyQ9aAqg=\" rel=\"nofollow\" target=\"_blank\">www.syndax.com\/<\/a>\u00a0or follow the Company on\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=RFlTGJjD65pKGkibFlJT_5hYSXVzK-TPt2wvlk7u9a4d5aBsO_HIpb1PIYnXgr00ZVodgfRDqhAmhzJvS8jxAg==\" rel=\"nofollow\" target=\"_blank\">X\u202f<\/a>and\u202f<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=XZXEQKvCsImadv5yLS4f-FV7pbV1n7sxeJtI9K9wp8oz5Q_KXEAvWadMVBAgYDodZmo4fRIUgisZ4Sz8HdR0Grj1w4BHUhVMZUzJ8K-K2bZy_bYHfXoFcF4m55pBiuuD\" rel=\"nofollow\" target=\"_blank\">LinkedIn<\/a>.<\/p>\n<p align=\"justify\">\n        <strong>Forward-Looking Statements<\/strong>\n      <\/p>\n<p align=\"justify\">This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;could,&#8221; &#8220;estimate,&#8221; &#8220;expects,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;plan,&#8221; &#8220;potential,&#8221; &#8220;predict,&#8221; &#8220;project,&#8221; &#8220;should,&#8221; &#8220;will,&#8221; &#8220;would&#8221; or the negative or plural of those terms, and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. These forward-looking statements are based on Syndax&#8217;s expectations and assumptions as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties. Actual results may differ materially from these forward-looking statements. Forward-looking statements contained in this press release include, but are not limited to, statements about the progress, timing, clinical development and scope of clinical trials, the reporting of clinical data for Syndax&#8217;s product candidates, the acceptance of Syndax and its partners&#8217; products in the marketplace, sales, marketing, manufacturing and distribution requirements, and the potential use of its product candidates to treat various cancer indications and fibrotic diseases. Many factors may cause differences between current expectations and actual results, including: unexpected safety or efficacy data observed during preclinical or clinical trials; clinical trial site activation or enrollment rates that are lower than expected; changes to Revuforj&#8217;s or Niktimvo\u2019s commercial availability; changes in expected or existing competition; changes in the regulatory environment; failure of Syndax&#8217;s collaborators to support or advance collaborations or product candidates; and unexpected litigation or other disputes. Other factors that may cause Syndax&#8217;s actual results to differ from those expressed or implied in the forward-looking statements in this press release are discussed in Syndax&#8217;s filings with the U.S. Securities and Exchange Commission, including the &#8220;Risk Factors&#8221; sections contained therein. Except as required by law, Syndax assumes no obligation to update any forward-looking statements contained herein to reflect any change in expectations, even as new information becomes available.<\/p>\n<p align=\"justify\">\n        <strong>Syndax Contact<\/strong>\n      <\/p>\n<p>Sharon Klahre<br \/>Syndax Pharmaceuticals, Inc.<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=jNOdPxdEFJiZuZYSdKugi90BGu2WILGVbH7TqdFkqNcEqEh6VBdpt4q9ltgzrgktkOHvnY4EXGD6YFwhSbfRPbtxWWzu2ciTHPoeu6JL5z0=\" rel=\"nofollow\" target=\"_blank\">sklahre@syndax.com<\/a><br \/>Tel 781.684.9827<\/p>\n<p>SNDX-G<\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcyNDMxOSM3NjE0NjgwIzIwMDQ4Mzk=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/MmI2MmU0ODUtNTlhOS00YmFmLWIzNzUtMDUyMjg4YmM1OGU0LTEwMTY0MTItMjAyNi0wNS0yMS1lbg==\/tiny\/Syndax-Pharmaceuticals-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>\u2013 Oral presentation will highlight favorable outcomes observed among 21 adults and children with KMT2Ar, NPM1m, or NUP98r acute leukemia who received revumenib post-transplant \u2013 \u2013 Data underscoring unique aspects of revumenib\u2019s PK profile, including the ability to administer it with gastric acid reducing agents and low-fat meals, will be presented \u2013 \u2013 Design of ongoing pivotal trials of revumenib plus low or high-intensity chemotherapy in newly diagnosed NPM1m or KMT2Ar acute leukemia will be highlighted \u2013 NEW YORK, May 21, 2026 (GLOBE NEWSWIRE) &#8212; Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced the acceptance of four Revuforj\u00ae (revumenib) abstracts for presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting, taking place &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/syndax-announces-four-revuforj-revumenib-abstracts-accepted-for-asco-2026-including-an-oral-presentation-of-post-transplant-data\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Syndax Announces Four Revuforj\u00ae (revumenib) Abstracts Accepted for ASCO 2026, Including an Oral Presentation of Post-Transplant Data&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-966235","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Syndax Announces Four Revuforj\u00ae (revumenib) Abstracts Accepted for ASCO 2026, Including an Oral Presentation of Post-Transplant Data - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/syndax-announces-four-revuforj-revumenib-abstracts-accepted-for-asco-2026-including-an-oral-presentation-of-post-transplant-data\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Syndax Announces Four Revuforj\u00ae (revumenib) Abstracts Accepted for ASCO 2026, Including an Oral Presentation of Post-Transplant Data - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"\u2013 Oral presentation will highlight favorable outcomes observed among 21 adults and children with KMT2Ar, NPM1m, or NUP98r acute leukemia who received revumenib post-transplant \u2013 \u2013 Data underscoring unique aspects of revumenib\u2019s PK profile, including the ability to administer it with gastric acid reducing agents and low-fat meals, will be presented \u2013 \u2013 Design of ongoing pivotal trials of revumenib plus low or high-intensity chemotherapy in newly diagnosed NPM1m or KMT2Ar acute leukemia will be highlighted \u2013 NEW YORK, May 21, 2026 (GLOBE NEWSWIRE) &#8212; Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced the acceptance of four Revuforj\u00ae (revumenib) abstracts for presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting, taking place &hellip; Continue reading &quot;Syndax Announces Four Revuforj\u00ae (revumenib) Abstracts Accepted for ASCO 2026, Including an Oral Presentation of Post-Transplant Data&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/syndax-announces-four-revuforj-revumenib-abstracts-accepted-for-asco-2026-including-an-oral-presentation-of-post-transplant-data\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-05-21T22:26:02+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcyNDMxOSM3NjE0NjgwIzIwMDQ4Mzk=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"11 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/syndax-announces-four-revuforj-revumenib-abstracts-accepted-for-asco-2026-including-an-oral-presentation-of-post-transplant-data\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/syndax-announces-four-revuforj-revumenib-abstracts-accepted-for-asco-2026-including-an-oral-presentation-of-post-transplant-data\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Syndax Announces Four Revuforj\u00ae (revumenib) Abstracts Accepted for ASCO 2026, Including an Oral Presentation of Post-Transplant Data\",\"datePublished\":\"2026-05-21T22:26:02+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/syndax-announces-four-revuforj-revumenib-abstracts-accepted-for-asco-2026-including-an-oral-presentation-of-post-transplant-data\\\/\"},\"wordCount\":2163,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/syndax-announces-four-revuforj-revumenib-abstracts-accepted-for-asco-2026-including-an-oral-presentation-of-post-transplant-data\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTcyNDMxOSM3NjE0NjgwIzIwMDQ4Mzk=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/syndax-announces-four-revuforj-revumenib-abstracts-accepted-for-asco-2026-including-an-oral-presentation-of-post-transplant-data\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/syndax-announces-four-revuforj-revumenib-abstracts-accepted-for-asco-2026-including-an-oral-presentation-of-post-transplant-data\\\/\",\"name\":\"Syndax Announces Four Revuforj\u00ae (revumenib) Abstracts Accepted for ASCO 2026, Including an Oral Presentation of Post-Transplant Data - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/syndax-announces-four-revuforj-revumenib-abstracts-accepted-for-asco-2026-including-an-oral-presentation-of-post-transplant-data\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/syndax-announces-four-revuforj-revumenib-abstracts-accepted-for-asco-2026-including-an-oral-presentation-of-post-transplant-data\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTcyNDMxOSM3NjE0NjgwIzIwMDQ4Mzk=\",\"datePublished\":\"2026-05-21T22:26:02+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/syndax-announces-four-revuforj-revumenib-abstracts-accepted-for-asco-2026-including-an-oral-presentation-of-post-transplant-data\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/syndax-announces-four-revuforj-revumenib-abstracts-accepted-for-asco-2026-including-an-oral-presentation-of-post-transplant-data\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/syndax-announces-four-revuforj-revumenib-abstracts-accepted-for-asco-2026-including-an-oral-presentation-of-post-transplant-data\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTcyNDMxOSM3NjE0NjgwIzIwMDQ4Mzk=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTcyNDMxOSM3NjE0NjgwIzIwMDQ4Mzk=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/syndax-announces-four-revuforj-revumenib-abstracts-accepted-for-asco-2026-including-an-oral-presentation-of-post-transplant-data\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Syndax Announces Four Revuforj\u00ae (revumenib) Abstracts Accepted for ASCO 2026, Including an Oral Presentation of Post-Transplant Data\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Syndax Announces Four Revuforj\u00ae (revumenib) Abstracts Accepted for ASCO 2026, Including an Oral Presentation of Post-Transplant Data - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/syndax-announces-four-revuforj-revumenib-abstracts-accepted-for-asco-2026-including-an-oral-presentation-of-post-transplant-data\/","og_locale":"en_US","og_type":"article","og_title":"Syndax Announces Four Revuforj\u00ae (revumenib) Abstracts Accepted for ASCO 2026, Including an Oral Presentation of Post-Transplant Data - Market Newsdesk","og_description":"\u2013 Oral presentation will highlight favorable outcomes observed among 21 adults and children with KMT2Ar, NPM1m, or NUP98r acute leukemia who received revumenib post-transplant \u2013 \u2013 Data underscoring unique aspects of revumenib\u2019s PK profile, including the ability to administer it with gastric acid reducing agents and low-fat meals, will be presented \u2013 \u2013 Design of ongoing pivotal trials of revumenib plus low or high-intensity chemotherapy in newly diagnosed NPM1m or KMT2Ar acute leukemia will be highlighted \u2013 NEW YORK, May 21, 2026 (GLOBE NEWSWIRE) &#8212; Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced the acceptance of four Revuforj\u00ae (revumenib) abstracts for presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting, taking place &hellip; Continue reading \"Syndax Announces Four Revuforj\u00ae (revumenib) Abstracts Accepted for ASCO 2026, Including an Oral Presentation of Post-Transplant Data\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/syndax-announces-four-revuforj-revumenib-abstracts-accepted-for-asco-2026-including-an-oral-presentation-of-post-transplant-data\/","og_site_name":"Market Newsdesk","article_published_time":"2026-05-21T22:26:02+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcyNDMxOSM3NjE0NjgwIzIwMDQ4Mzk=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"11 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/syndax-announces-four-revuforj-revumenib-abstracts-accepted-for-asco-2026-including-an-oral-presentation-of-post-transplant-data\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/syndax-announces-four-revuforj-revumenib-abstracts-accepted-for-asco-2026-including-an-oral-presentation-of-post-transplant-data\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Syndax Announces Four Revuforj\u00ae (revumenib) Abstracts Accepted for ASCO 2026, Including an Oral Presentation of Post-Transplant Data","datePublished":"2026-05-21T22:26:02+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/syndax-announces-four-revuforj-revumenib-abstracts-accepted-for-asco-2026-including-an-oral-presentation-of-post-transplant-data\/"},"wordCount":2163,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/syndax-announces-four-revuforj-revumenib-abstracts-accepted-for-asco-2026-including-an-oral-presentation-of-post-transplant-data\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcyNDMxOSM3NjE0NjgwIzIwMDQ4Mzk=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/syndax-announces-four-revuforj-revumenib-abstracts-accepted-for-asco-2026-including-an-oral-presentation-of-post-transplant-data\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/syndax-announces-four-revuforj-revumenib-abstracts-accepted-for-asco-2026-including-an-oral-presentation-of-post-transplant-data\/","name":"Syndax Announces Four Revuforj\u00ae (revumenib) Abstracts Accepted for ASCO 2026, Including an Oral Presentation of Post-Transplant Data - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/syndax-announces-four-revuforj-revumenib-abstracts-accepted-for-asco-2026-including-an-oral-presentation-of-post-transplant-data\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/syndax-announces-four-revuforj-revumenib-abstracts-accepted-for-asco-2026-including-an-oral-presentation-of-post-transplant-data\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcyNDMxOSM3NjE0NjgwIzIwMDQ4Mzk=","datePublished":"2026-05-21T22:26:02+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/syndax-announces-four-revuforj-revumenib-abstracts-accepted-for-asco-2026-including-an-oral-presentation-of-post-transplant-data\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/syndax-announces-four-revuforj-revumenib-abstracts-accepted-for-asco-2026-including-an-oral-presentation-of-post-transplant-data\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/syndax-announces-four-revuforj-revumenib-abstracts-accepted-for-asco-2026-including-an-oral-presentation-of-post-transplant-data\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcyNDMxOSM3NjE0NjgwIzIwMDQ4Mzk=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcyNDMxOSM3NjE0NjgwIzIwMDQ4Mzk="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/syndax-announces-four-revuforj-revumenib-abstracts-accepted-for-asco-2026-including-an-oral-presentation-of-post-transplant-data\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Syndax Announces Four Revuforj\u00ae (revumenib) Abstracts Accepted for ASCO 2026, Including an Oral Presentation of Post-Transplant Data"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/966235","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=966235"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/966235\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=966235"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=966235"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=966235"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}